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Microvesicles (MVs) are released by most cell types in physiological conditions, but their
number is often increased upon cellular activation or neoplastic transformation. This sug-
gests that their detection may be helpful in pathological conditions to have information on
activated cell types and, possibly, on the nature of the activation.This could be of paramount
importance in districts and tissues that are not accessible to direct examination, such as
the central nervous system. Increased release of MVs has been described to be associated
to the acute or active phase of several neurological disorders. While the subcellular origin
of MVs (exosome or ectosomes) is basically never addressed in these studies because of
technical limitations, the cell of origin is always identiﬁed. Endothelium- or platelet-derived
MVs, detected in plasma or serum, are linked to neurological pathologies with a vascular
or ischemic pathogenic component, and may represent a very useful marker to support
therapeutic choices in stroke. In neuroinﬂammatory disorders, such as multiple sclero-
sis, MVs of oligodendroglial, or microglial origin have been described in the cerebrospinal
ﬂuid and may carry, in perspective, additional information on the biological alterations in
their cell of origin. Little speciﬁc evidence is available in neurodegenerative disorders and,
speciﬁcally, MVs of neural origin have never been investigated in these pathologies. Few
data have been reported for neuroinfection and brain trauma. In brain tumors, despite the
limited number of studies performed, results are very promising and potentially close to
clinical translation. We here review all currently available data on the detection of MVs in
neurological diseases, limiting our search to exclusively human studies. Current literature
and our own data indicate that MVs detection may represent a very promising strategy to
gain pathogenic information, identify therapeutic targets, and select speciﬁc biomarkers
for neurological disorders.
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INTRODUCTION
Microvesicles (MVs) have gained recently large attention as both
potential biomarkers, and a tool to investigate the biology of cells
from sites difﬁcult to reach in vivo. Solid tumors, for example,
display an elusive nature of transformed cells, grow into organs,
and re-appear in unpredictable sites when producing metastases.
By releasing massive amounts of MVs, however, they may reveal
their presence. Investigating the content of these vesicles, infor-
mation may be gained on biological processes occurring within
the tumor mass. Similarly, in diseases of the central nervous
system (CNS), a part from post-mortem examination, neuro-
scientists, and neurologists do not have access to the diseased
tissue with the extreme exception of cases that need a cerebral
biopsy, which are usually not representative of the most common
neurological disorders. Therefore, here also, MVs, that are phys-
iologically released by all neural and non-neural cells within the
CNS (Figure 1), hold promise as possible vehicle of clinical and
biological information. The difﬁculties related to the detection
and analysis of MVs in neurological disorders are partially over-
lapping with those found in other diseases, and partially peculiar.
In fact there are common problems of general inadequacy of avail-
able detection techniques. It is now a general consensus that ﬂow
cytometry (FACS) is unable to detect properly small exosomes
(Figure 2), but only can reliably analyze ectosomes (Figure 2),
also called shed vesicles. Further, as compared to tumor cells,
platelets, or endothelial cells, neural cells release very reduced
amounts of MVs, posing also a problem of detection limit. Finally,
the most interesting compartment to examine, the cerebrospinal
ﬂuid (CSF), cannot be sampled serially without posing an ethi-
cal problem. Nevertheless, the possibility to access these complex
cargo structures, storing a multiplicity of signals derived from
un-accessible cells, gives the possibility to get very relevant infor-
mation on their cell of origin during disease. Upon proper inter-
pretation, these evidences may yield data with clinical diagnostic
and prognostic value, provide information to stratify patients con-
cerning response to treatments, or even suggest new therapeutic
targets.
Investigations have already been performed in this respect and
we are going to review available evidence for MVs of different cel-
lular and subcellular origin, and detected by different techniques,
in different compartments, as potential biomarkers in neurological
disorders (Table 1).
CEREBROVASCULAR DISORDERS
Thenumber of MVsderived fromendothelial cells or platelets have
been linked to the extent of myocardial infarcts (Mallat et al., 2000;
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FIGURE 1 | All neural cell types release microvesicles (MVs).The CNS
parenchyma is very complex in terms of cellular composition. This cartoon
depicts neurons (blue cells), their axons surrounded by myelin produced by
oligodendrocytes (gray cells), ramiﬁed microglia (green cells), astrocytes
(yellow cells), and blood vessels (in red). Still, this is a very simpliﬁed
representation of CNS tissue. All represented, and not represented, cell
types are able to release MVs delivering signals to neighboring cells and
into the environment (van der Vos et al., 2011). Some of these MVs are
drained to accessible biological ﬂuids like the blood or the cerebrospinal
ﬂuid, where they might constitute a new class of biomarkers.
Jung et al., 2012). Similarly, their number has been investigated by
several groups in cerebral ischemia.
Already in the early 1990s, Ahn and co-workers found that
platelet-derived MVs, stained for CD42 and detected by FACS, are
increased in plasma of patients with ischemic stroke, especially
in those with transitory ischemic attacks or with lacunar infarcts,
as compared to those with thrombosis of large vessels (Lee et al.,
1993). In this ﬁrst, pioneering study, however, no correlations had
been drawn with the extent of the ischemic area, or the severity of
the outcome (Lee et al., 1993). These results have been conﬁrmed,
over 10 years later, using CD61 and CD62P to identify MVs of
platelets origin, in whole blood of patients with ischemic stroke
(Cherian et al., 2003; Pawelczyk et al., 2009). These two reports dis-
cuss their results associating increased platelet activation, testiﬁed
by the increased release of MVs, with higher risk of developing
stroke. They therefore propose to use the detection of platelet-
derived MVs as a biomarker to be used in a population at risk to
have a stroke, to identify individuals with higher chance, or partic-
ularly close to develop the event. Two groups in Japan have used
an interesting, alternative, technical approach to overcome some
of the limitations of ﬂow cytometry in measuring platelet-derived
MVs. By ELISA they quantify the platelet marker CD42a or CD42
on ultracentrifugated plasma MVs, conﬁrming the positive asso-
ciation of these markers with the occurrence of ischemic stroke
(Shirafuji et al., 2008; Kuriyama et al., 2010). From these studies
we can conclude that platelet-derived MVs are studied to dissect
the contribution of platelets to the pro-thrombotic state leading
to stroke, but, judging from available literature, appear of limited
clinical usefulness as biomarkers.
FIGURE 2 | Microvesicles are of different subcellular origin. MVs
released from various neural cell types have different subcellular origin. In
the present review we consider ectosomes, also called shed vesicles, and
exosomes. Ectosomes shed from the plasma membrane carrying along
transmembrane proteins, and soluble proteins, nucleic acids, and
metabolites present in the cytoplasm. Ectosomes are large and
heterogeneous in size. Exosomes derive from the release of multivesicular
bodies, an intracellular organel along the endocytic pathway, that controls
membrane composition and content. Exosomes are small and
homogenous in size.
Endothelium-derived MVs, recently identiﬁed and linked to
cerebral ischemia, may be more promising. The ﬁrst available
report associated the number of endothelial MVs, identiﬁed in
plasma by FACS staining for CD105, CD144, phosphadityl ser-
ine (PS), and CD54, with several clinical parameters, including
stroke size, severity, and outcome (Simak et al., 2006). In partic-
ular, lesion volume appeared to be in direct correlation with the
number of CD105+,CD54+, PS+, but notCD144+ MVs.CD144+
MVs, on the other hand, predict the hemorrhagic transformation
of the ischemic lesion (Simak et al., 2006). Contrasting results were
reported 1 year later, when similar CD31+ or CD62E+endothelial
MVs levels were described in acute ischemic stroke patients and in
stroke mimics, i.e., patients with stroke-like symptoms but appar-
ently without ischemic lesions (Williams et al., 2007). The lack
of a real consensus on the deﬁnition of stroke mimics (poten-
tially affected by transitory ischemic attack?), and several technical
limitations, including the use of archival samples stored frozen
for over 1 year, however, limit the interpretation of these data.
More recently, Jung et al. (2009) have substantially conﬁrmed
the original ﬁnding. In fact, they describe elevated endothelium-
derived MVs to be signiﬁcantly associated to stenosis of both
intra- and extra-cranial portions of cerebral arteries. Further they
associate distinct MVs markers for extra-cranial (CD62E+) and
intra-cranial (CD31+CD42b−PS+) localization of the stenosis.
This study also conﬁrms a positive correlation of the number
of plasma endothelial MVs and infarct size and clinical sever-
ity. Analysis of predictive parameters in patients already carrying
risk factors showed that plasma levels of endothelial MVs were
inversely correlated with the time of occurrence of an ischemic
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Table 1 | MVs in neurological diseases.
Disease Site and detection Cell of origin MPs modulation References
CEREBROVASCULAR DISORDERS
Ischemic stroke Plasma by FACS Platelets ↑ CD42+ Lee et al. (1993)
Ischemic stroke Blood by FACS Platelets ↑ CD61+ Cherian et al. (2003), Pawelczyk et al.
(2008)↑ CD62P+
Ischemic stroke Plasma by ELISA Platelets ↑ CD42a+ Shirafuji et al., 2008
Ischemic stroke Plasma by ELISA Platelets ↑ CD42+ Kuriyama et al. (2010)
Ischemic stroke Plasma by FACS Endothelium ↑ CD105+CD41a−CD45− Simak et al. (2006)
↑ CD105+CD144+
↑ CD105+PS+CD41a
↑ CD105+CD54+CD45
Strokes mimics Plasma by FACS Endothelium ↑ CD31+ Williams et al. (2007)
↑ CD62E+
Intracranial arterial stenosis Plasma by FACS Endothelium ↑ CD31+CD42b Jung et al. (2009)
↑ CD31+PS+
Extracranial arterial stenosis Plasma by FACS Endothelium ↑ CD62E+ Jung et al. (2009)
Cerebral vasospasm Plasma by FACS Endothelium ↑ CD105+PS+ Lackner et al. (2010)
↑ CD62E+
↑ CD106+
Cerebral infarction following
vasospasm
Plasma by FACS Platelets ↑ CD41+ Lackner et al. (2010)
NEUROINFLAMMATORY DISEASES
Multiple sclerosis CSF by electron microscopy Oligodendrocytes ↑ Unknown Scolding et al. (1989)
Multiple sclerosis Plasma by FACS Endothelium ↑ CD31+CD42− Minagar et al. (2001)
↑ CD51+
Multiple sclerosis Blood by FACS Endothelium ↑ CD54+ Jy et al. (2004)
↑ CD62E+
Multiple sclerosis Plasma by FACS Platelets ↑ CD62P+ Sheremata et al. (2008)
Cerebral malaria Plasma by FACS Endothelium ↑ CD51+ Combes et al. (2004)
NEURODEGENERATIVE DISORDERS
Alzheimer CSF by WB Neurons? ↑ Phospho-tau Saman et al. (2012)
Alzheimer Blood by FACS Platelets No modulation Lee et al. (1993), Sevush et al. (1998)
Vascular dementia Plasma by FACS Platelets ↑ CD42+ Lee et al. (1993)
EPILEPSY
Temporal lobe epilepsy CSF by immunoblotting Stem cells ↑ CD133+ Huttner et al. (2012)
BRAINTUMORS
Glioblastoma Biopsies by electron microscopy Tumor cells ↑ Membrane blebs González-Cámpora et al. (1978)
Glioblastoma CSF by immunoblotting Stem cells ↑ CD133+ Huttner et al. (2008)
Glioblastoma Serum and biopsies by RT-PCR Tumor cells ↑ EGFRvIII+ Skog et al. (2008)
TRAUMA
Traumatic brain injury CSF and plasma by
prothrombinase assay
Platelets and
endothelium
↑ CD42+ Morel et al. (2008)
↑ CD31+
stroke (Jung et al., 2009). The predictive value of endothelial MVs
(deﬁned as CD105+PS+, CD62E+, or CD106+), has been con-
ﬁrmed in a different clinical setting, namely the risk to develop
cerebral vasospasm in patients with spontaneous subarachnoid
hemorrhage (Lackner et al., 2010), in which also platelet-derived
MVsmay play a role (Lackner et al., 2010). The recent introduction
of treatments of the acute phase of ischemic stroke, for example
systemic thrombolysis, indicates the need for biomarkers able to
stratify patients and minimize side effects of these therapies. Fur-
ther, the identiﬁcation of patients in which the risk for ischemic
stroke is so high that itmight beworth treatingwith anticoagulants
could be a very powerful preventive strategy. Plasma endothe-
lial MVs levels may potentially represent a solid biomarker for
these two conditions. Investigations to validate this concept are
conducted in several centers.
NEUROINFLAMMATORY DISEASES
With the introduction of MRI, and especially gadolinium-
enhanced MRI, the ﬁeld of neuroinﬂammation has found a gold
standard biomarker providing localization, structural (or even
www.frontiersin.org March 2012 | Volume 3 | Article 63 | 3
Colombo et al. Microvesicles in neurology
ultrastructural), molecular, and functional information. Perfor-
mances of MRI are still increasing and its potential has not been
fully exploited, since new sequences, providing new information,
are constantly developed.What is the need, then, for new biomark-
ers in neuroinﬂammation? MRI is very costly, difﬁcult to perform
on all patients in the emergency room, and, for the moment, pro-
vides very little information on the biological status of single cell
types. MVs hold the potential to ﬁll this gap, providing quantita-
tive and qualitative information on distinct cell types selectively
involved in CNS pathologies.
The pioneering work in this ﬁeld was published over 20 years
ago, describing MVs of oligodendroglial origin in the CSF of
patients affected by multiple sclerosis (MS; Scolding et al., 1989).
Authors discussed their ﬁndings in the perspective of dissecting
the effector mechanisms leading to myelin destruction, rather
than as potential biomarkers for MS. The reason, among others,
may rely on the fact that CSF is not a readily accessible biolog-
ical ﬂuid and repeated sampling, as mentioned above, poses an
ethical issue. On the other hand, inﬂammatory events occurring
in the CNS may produce biomarkers that are rapidly diluted in
the circulation and difﬁcult to detect in peripheral ﬂuids, such as
plasma, displaying high background noise levels for most mark-
ers. Nevertheless, CD31+ endothelial MVs, identiﬁed in plasma
samples by FACS, have been associated to clinical and neuroradi-
ological exacerbation of MS, while CD51+ endothelial MVs have
been found elevated in both relapsing and remitting MS patients
as compared to controls (Minagar et al., 2001). The same group
has conﬁrmed their ﬁndings in 2004, further describing that most
endothelial MVs can be detected in the blood in the form of conju-
gates with other cells, especially monocytes (Jy et al., 2004), while
described that, similarly to stroke, platelet-derived MVs, despite
elevated in the plasma of MS patients as compared to controls, dis-
play a reduced discriminating power between health and disease
(Sheremata et al., 2008).
Endothelium-derived MVs have been investigated also in cere-
bral malaria, a complication of malaria occurring in about 1% of
patients infected with Plasmodium Falciparum and in which the
endothelium of small cerebral vessels appears to play a crucial role
(Milner, 2010). Indeed, endothelial MVs, detected by FACS stain-
ing for CD51, are selectively increased in plasma of patients with
cerebral malaria and in patients with both coma and severe ane-
mia, as compared to patients with uncomplicated malaria or only
with severe anemia (Combes et al., 2004). Further, the number of
plasma endothelial MVs normalizes upon treatment, suggesting a
possible role also as biomarkers for therapeutic efﬁcacy (Combes
et al., 2004).
A common feature of all neuroinﬂammatory diseases is the
primary involvement of the prototypical immune neural cell
type: microglia. Practically indistinguishable from peripheral tis-
sue macrophages using common markers, not accessible due to
anatomical reasons, the only current way to gain information
on microglia activation in vivo is by positron emission tomog-
raphy using the tracer [11C](R)-PK11195 (Kannan et al., 2009).
We have recently described that microglia derived MVs, identi-
ﬁed by FACS staining for IB4, are dramatically increased in the
CSF of patients with neuroinﬂammatory diseases such as patients
affected by relapsing MS,neuromyelitis optica,meningitis (RF and
CV personal communication). Our clinical and experimental data
suggest that microglial MVs may be a solid marker for disease sta-
tus and response to therapies,with all the limitations of biomarkers
in the CSF that we have discussed above.
NEURODEGENERATIVE DISORDERS
Little evidence is available in the literature for MVs alterations
in neurodegeneration. In Alzheimer’s disease, negative results for
platelet-derived MVs have been reported, demented patients dis-
playing MVs levels overlapping to healthy individuals (Lee et al.,
1993; Sevush et al., 1998). A very recent report, however, describes
that in early Alzheimer it is possible to detect increased levels of
phosphorylated tau protein in the exosome fraction of the CSF
(Saman et al., 2012). This is a very promising ﬁnding, and points to
the possibility for an early diagnosis of AD through CSF MVs con-
tent. For amyotrophic lateral sclerosis, experimental data in vitro
on mice tissue suggest the possible increase in motoneuron-
derived apoptotic MVs (Appert-Collin et al., 2006), but no human
follow-up studies have been performed. Thus, the only positive
available evidence is for vascular,multi-infarct, dementia in which
elevated platelet-derived MVV have been reported (Lee et al.,
1993), in line with data available for cerebral ischemia, of which
vascular dementia is a chronic form. Since so little work has
been done so far, neurodegeneration appears, in perspective, an
interesting ﬁeld to investigate MVs.
EPILEPSY
Epilepsy is, of course, mostly a clinical diagnosis and is monitored
by electroencephalography. Stratiﬁcation of patients in clinical
subtypes is, however, not always trivial. Notably, MVs positive
for the stem cell marker prominin-1/CD133, likely derived from
neural stem cells or ependymal cells, have been found elevated in
the CSF of patients with partial temporal, but not extra-temporal,
epilepsy (Huttner et al., 2012). CD133+ MVs CSF levels were simi-
larly increased in cryptogenetic forms or in patients were temporal
epilepsy was secondary to neoplasms dysplasia, or hippocampal
sclerosis (Huttner et al., 2012).
BRAIN TUMORS
Brain tumor diagnosis and monitoring is usually performed by
neuroradiology, with the need in certain circumstances to per-
form an invasive cerebral biopsy. A pioneering work by Roy
Weller and collaborators, suggested already in 1978 the existence
of glioblastoma-derived MVs (Gonzalez-Campora et al., 1978). In
fact, by scanning electron microscopy they described, on human
glioblastoma biopsy samples, the presence of several membrane
alterations such as microvilli, blebs, and rufﬂes, suggesting a high
motility of cell membranes. MVs close to shed from the cell mem-
brane are clearly depicted in electron scans of this work (Gonzalez-
Campora et al., 1978). Evidence for glioblastoma-derived MVs in
biological ﬂuids are, however, very recent. Huttner et al. (2008)
have quantiﬁed, by immunoblotting, prominin-1/CD133+in MVs
puriﬁed by ultracentrifugation from CSF samples. They show that
prominin-1/CD133 levels are very high in CSF MVs from patients
with glioblastoma as compared to healthy individuals. More use-
ful in a clinical setting may be the ﬁnding by Skog et al. (2008)
that it is possible to detect, by nested PCR, the transcript coding
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for the oncogenic form of the epidermal growth factor receptor
EGFRvIII in MVs puriﬁed by ultracentrifugation from serum of a
subgroup of patients with glioblastoma. This opens the possibility
to use a serumbiomarker, carried by glioblastoma-derivedMVs, to
support diagnosis in case of uncertain neuroradiological images,
by avoiding invasive procedures such as cerebral biopsy, and to
monitor therapeutic efﬁcacy or the appearance of recurrences.
TRAUMATIC BRAIN INJURY
Traumatic brain injury may, besides acute lesions, determine sec-
ondary cellular and vascular damage leading to poor clinical out-
come. Morel and co-authors described that in the CSF and in the
plasma of patients with traumatic brain injury, PS+ MVs, deﬁned
as pro-coagulant by a functional assay, increase and peak in the
acute phase, returning to basal levels within 10 days (Morel et al.,
2008). The cellular origin of theseMVshas been deﬁned by captur-
ing them with platelet and endothelial plastic-bound speciﬁc anti-
bodies. Patients with persistent high CSF levels of these MVs dis-
played a poor clinical outcome. Thus, CSF endothelial or platelet-
derived MVs may help identify those traumatic patients that need
special care because of their high risk to develop secondary events
leading to a fatal outcome or severe neurological deﬁcit.
CONCLUSION
As can be learned from this review, MVs have not been widely
investigated as potential biomarkers in neurological disorders,
although the ﬁrst evidence of their existence in the CNS was pro-
vided several decenniums ago. The most striking limit of current
available reports is that, apart from glioblastoma tumor cells,MVs
from very few, actually only two CNS speciﬁc cell types have been
investigated for release in humans, namely oligodendrocytes and
microglia. In fact, most studies mentioned in this review deal with
MVs released by endothelium or platelets, and translate to the
brain concepts that had been developed principally for myocar-
dial infarct. The main reason for this may rely on the fact that,
in general, neural cells generally release low amounts of MVs as
compared to endothelium, platelets, stem cells, or tumor cells.
Therefore,brain speciﬁcMVsare verydiluted, if present, inperiph-
eral biological ﬂuids such as blood, plasma, or serum, thus making
very difﬁcult their detection by current available technologies. On
the other hand, endothelium and platelets, and even microglia,
are involved in most pathological processes occurring within the
CNS. Thus, even if detected in the CSF, MVs derived from these
cell types are likely to be non-speciﬁcally altered in the course of
different neurological diseases.
Nevertheless, detection of MVs as biomarkers for neurologi-
cal disorders is very promising in perspective. The development
of new detection systems, speciﬁcally designed for MVs, with
increased sensitivity and able to stratify MVs according to size
and cellular origin, may considerably improve our ability to asso-
ciate a certain MVs pattern to a speciﬁc pathological condition.
The main goal to gain disease speciﬁcity is, however, identiﬁcation
of the content of MVs. It is reasonable to think that MVs of neural
origin carry different molecules in different diseases and even in
different disease phases. Further, the unique possibility to obtain
from MVs in vivo information on brain cells involved in patho-
logical processes may shed light on the pathogenesis of currently
elusive pathologies such as primary neurodegenerative disorders,
i.e., Alzheimer’s, Parkinson’s, ALS, etc. In some of these disorders
MVs themselves may play a role in pathogenesis, and thus con-
stitute a novel therapeutic target, once the biology of their release
will be dissected in more detail (Bianco et al., 2009).
From the neurologist’s perspective, validated, routinely avail-
able, detection techniques for MVs may be very interesting in
stroke, where they may constitute an additional paraclinical para-
meter to evaluate when deciding therapeutic strategies, or to
identify patients at high risk for a poor clinical outcome. In brain
tumors the possibility to avoid brain biopsy and tomonitor disease
progression through MVs only depends from the detection lim-
its, since tumor-speciﬁcMVs bearing speciﬁcmarkers have already
been identiﬁed, andmay indeed constitute a valuable tool in future
clinical neurology. In neuroinﬂammation the role for MVs may be
more difﬁcult to deﬁne, since solid biomarkers, such as MRI, are
already available, and microglial MVs in the CSF, despite holding
promise, may remain a non-speciﬁc parameter, helpful but not
decisive to make diagnosis and difﬁcult to use for monitoring.
Detection of MVs from neural cell origin may be extremely useful
in neuroinfection, especially in those cases were the pathogen may
be elusive, since it is known that MVs are carriers for infectious
agents, and isolation of MVs from the CSF may help to increase
signiﬁcantly the sensitivity of available tests.
In conclusion, MVs already represent an interesting biomarker
in neurology. To make their detection a routine procedure in the
clinics, we need a change of gears in the development of speciﬁc
technologies able to increase the performances of currently avail-
able assays. This would probably allow also more investigations in
neglected ﬁelds like neurodegeneration, that however constitute
one of the major challenges for research in medical neurosciences.
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